Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Immunogenicity of HIV-1 envelope glycoprotein oligomers.

Forsell MN, Schief WR, Wyatt RT.

Curr Opin HIV AIDS. 2009 Sep;4(5):380-7. doi: 10.1097/COH.0b013e32832edc19. Review.

PMID:
20048701
2.

Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization.

Dosenovic P, Chakrabarti B, Soldemo M, Douagi I, Forsell MN, Li Y, Phogat A, Paulie S, Hoxie J, Wyatt RT, Karlsson Hedestam GB.

J Immunol. 2009 Sep 1;183(5):3373-82. doi: 10.4049/jimmunol.0900407.

3.

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.

Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B, Montefiori DC, Binley JM, Shaw GM, Haynes BF, Mascola JR, Morris L.

J Virol. 2009 Sep;83(17):8925-37. doi: 10.1128/JVI.00758-09. Epub 2009 Jun 24.

4.

Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site.

Dey B, Svehla K, Xu L, Wycuff D, Zhou T, Voss G, Phogat A, Chakrabarti BK, Li Y, Shaw G, Kwong PD, Nabel GJ, Mascola JR, Wyatt RT.

PLoS Pathog. 2009 May;5(5):e1000445. doi: 10.1371/journal.ppat.1000445. Epub 2009 May 29.

5.

ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.

Schnurr M, Orban M, Robson NC, Shin A, Braley H, Airey D, Cebon J, Maraskovsky E, Endres S.

J Immunol. 2009 Feb 1;182(3):1253-9. Erratum in: J Immunol. 2009 Apr 15;182(8):5152.

6.

Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.

Mörner A, Douagi I, Forsell MN, Sundling C, Dosenovic P, O'Dell S, Dey B, Kwong PD, Voss G, Thorstensson R, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

J Virol. 2009 Jan;83(2):540-51. doi: 10.1128/JVI.01102-08. Epub 2008 Nov 12.

7.

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.

Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, Connors M, Hoxie J, Mascola JR, Wyatt R.

J Virol. 2009 Jan;83(2):1045-59. doi: 10.1128/JVI.01992-08. Epub 2008 Nov 12.

8.

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L.

J Virol. 2009 Jan;83(2):757-69. doi: 10.1128/JVI.02036-08. Epub 2008 Nov 5. Erratum in: J Virol. 2009 May;83(9):4713-5.

9.

Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers.

Chen W, Zhu Z, Feng Y, Dimitrov DS.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17121-6. doi: 10.1073/pnas.0805297105. Epub 2008 Oct 28.

10.

B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4.

Forsell MN, Dey B, Mörner A, Svehla K, O'dell S, Högerkorp CM, Voss G, Thorstensson R, Shaw GM, Mascola JR, Karlsson Hedestam GB, Wyatt RT.

PLoS Pathog. 2008 Oct 3;4(10):e1000171. doi: 10.1371/journal.ppat.1000171.

11.

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR.

J Virol. 2008 Dec;82(23):11651-68. doi: 10.1128/JVI.01762-08. Epub 2008 Sep 24.

12.

Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.

Wu X, Sambor A, Nason MC, Yang ZY, Wu L, Zolla-Pazner S, Nabel GJ, Mascola JR.

Virology. 2008 Oct 25;380(2):285-95. doi: 10.1016/j.virol.2008.07.007. Epub 2008 Sep 18.

13.

Molecular architecture of native HIV-1 gp120 trimers.

Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S.

Nature. 2008 Sep 4;455(7209):109-13. doi: 10.1038/nature07159. Epub 2008 Jul 30.

14.

The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.

Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT.

Nat Rev Microbiol. 2008 Feb;6(2):143-55. doi: 10.1038/nrmicro1819. Review.

PMID:
18197170
15.

Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4.

Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, Hussan SS, Stanfield RL, Robinson J, Sodroski J, Wilson IA, Wyatt R, Bewley CA, Kwong PD.

Science. 2007 Sep 28;317(5846):1930-4.

16.

Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, Wu X, Shaw GM, Connors M, Wyatt RT, Mascola JR.

Nat Med. 2007 Sep;13(9):1032-4. Epub 2007 Aug 26.

17.

Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.

Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, Karim SS, Williamson C, Morris L; CAPRISA 002 Study Team.

J Virol. 2007 Jun;81(12):6187-96. Epub 2007 Apr 4.

18.

Structural definition of a conserved neutralization epitope on HIV-1 gp120.

Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD.

Nature. 2007 Feb 15;445(7129):732-7.

19.

Vaccine-delivered HIV envelope inhibits CD4(+) T-cell activation, a mechanism for poor HIV vaccine responses.

Fernando K, Hu H, Ni H, Hoxie JA, Weissman D.

Blood. 2007 Mar 15;109(6):2538-44. Epub 2006 Dec 7.

20.

Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.

Shu Y, Winfrey S, Yang ZY, Xu L, Rao SS, Srivastava I, Barnett SW, Nabel GJ, Mascola JR.

Vaccine. 2007 Feb 9;25(8):1398-408. Epub 2006 Nov 7.

Supplemental Content

Support Center